These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 35703556)

  • 21. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
    Hu L; Xu Y; Wu L; Feng J; Zhang L; Tang Y; Zhao X; Mai R; Chen L; Mei L; Tan Y; Du Y; Zhen Y; Su W; Peng T
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.
    Fiedler S; Piziorska MA; Denninger V; Morgunov AS; Ilsley A; Malik AY; Schneider MM; Devenish SRA; Meisl G; Kosmoliaptsis V; Aguzzi A; Fiegler H; Knowles TPJ
    ACS Infect Dis; 2021 Aug; 7(8):2362-2369. PubMed ID: 33876632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease.
    Dailey J; Kozhaya L; Dogan M; Hopkins D; Lapin B; Herbst K; Brimacombe M; Grandonico K; Karabacak F; Schreiber J; Liang BT; Salazar JC; Unutmaz D; Hyams JS
    Inflamm Bowel Dis; 2022 Jul; 28(7):1019-1026. PubMed ID: 34528661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 spike protein variant binding affinity to an angiotensin-converting enzyme 2 fusion glycoproteins.
    Matthews AM; Biel TG; Ortega-Rodriguez U; Falkowski VM; Bush X; Faison T; Xie H; Agarabi C; Rao VA; Ju T
    PLoS One; 2022; 17(12):e0278294. PubMed ID: 36472974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).
    Lee JH; Choi M; Jung Y; Lee SK; Lee CS; Kim J; Kim J; Kim NH; Kim BT; Kim HG
    Biosens Bioelectron; 2021 Jan; 171():112715. PubMed ID: 33099241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced Binding between Omicron B.1.1.529 and the Human ACE2 Receptor in a Surrogate Virus Neutralization Test for SARS-CoV-2.
    Hoffman T; Kolstad L; Akaberi D; Järhult JD; Rönnberg B; Lundkvist Å
    Viruses; 2023 May; 15(6):. PubMed ID: 37376580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors.
    Weidenbacher PA; Waltari E; de Los Rios Kobara I; Bell BN; Morris MK; Cheng YC; Hanson C; Pak JE; Kim PS
    Nat Chem Biol; 2022 Nov; 18(11):1270-1276. PubMed ID: 36076082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
    Laurie MT; Liu J; Sunshine S; Peng J; Black D; Mitchell AM; Mann SA; Pilarowski G; Zorn KC; Rubio L; Bravo S; Marquez C; Sabatino JJ; Mittl K; Petersen M; Havlir D; DeRisi J
    J Infect Dis; 2022 Jun; 225(11):1909-1914. PubMed ID: 34979030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.
    Agudelo M; Muecksch F; Schaefer-Babajew D; Cho A; DaSilva J; Bednarski E; Ramos V; Oliveira TY; Cipolla M; Gazumyan A; Zong S; Rodrigues DAS; Lira GS; Conde L; Aguiar RS; Ferreira OC; Tanuri A; Affonso KC; Galliez RM; Castineiras TMPP; Echevarria-Lima J; Bozza MT; Vale AM; Bieniasz PD; Hatziioannou T; Nussenzweig MC
    J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35796685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19.
    Liu WD; Wang JT; Chao TL; Ieong SM; Tsai YM; Kuo PH; Tsai MJ; Chen YJ; Li GC; Ho SY; Chen HH; Huang YS; Hung CC; Chen YC; Chang SY; Chang SC
    J Formos Med Assoc; 2023 Aug; 122(8):714-722. PubMed ID: 36496300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity.
    Nielsen SS; Vibholm LK; Monrad I; Olesen R; Frattari GS; Pahus MH; Højen JF; Gunst JD; Erikstrup C; Holleufer A; Hartmann R; Østergaard L; Søgaard OS; Schleimann MH; Tolstrup M
    EBioMedicine; 2021 Jun; 68():103410. PubMed ID: 34098342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants.
    Kubale J; Gleason C; Carreño JM; Srivastava K; Singh G; ; Gordon A; Krammer F; Simon V
    mBio; 2022 Oct; 13(5):e0178422. PubMed ID: 35997286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients.
    Ruetalo N; Businger R; Althaus K; Fink S; Ruoff F; Pogoda M; Iftner A; Ganzenmüller T; Hamprecht K; Flehmig B; Bakchoul T; Templin MF; Schindler M
    mSphere; 2021 Feb; 6(1):. PubMed ID: 33627511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.